Reading the tape
NASDAQ: REVB
Revelation Biosciences, Inc.
Healthcare · Biotechnology
Data caution
Per-share valuation inputs need verification
Event dated Dec 31, 2025Market-derived shares outstanding and recent statement shares differ materially. Per-share ratios and valuation outputs may be unreliable until the share base is verified. This sometimes appears with ADRs or provider share-count gaps.
Market Cap
$3.98M
52w High
$40.08
52w Low
$0.99
P/E
-0.07
Volume
45.77K
Outstanding Shares
3.72M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -96.85%Revenue (TTM): -100%FCF (TTM): 54.91%
What changed
The stock fell 96.85% over the last year. Revenue declined 100% over the trailing twelve months. Free cash flow grew 54.91% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive move in revenue — currently down 100% — would be the clearest signal to resolve the ambiguity.
Company profile
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics.
CEOJames Rolke
SectorHealthcare
IndustryBiotechnology
Employees8
IPO dateNov 17, 2020
Valuation
Forward P/E—
EV/EBITDA0.88
Enterprise value-$7.97M
Stock splits
Jan 28, 2026↓ Reverse
Every 4 shares became 1
Jul 7, 2025↓ Reverse
Every 3 shares became 1
Jan 28, 2025↓ Reverse
Every 16 shares became 1
Jan 25, 2024↓ Reverse
Every 30 shares became 1
Feb 1, 2023↓ Reverse
Every 35 shares became 1
Profitability & growth
Revenue growth-100%
Gross margin0%
Operating margin0%
ROE-100.59%▲68.51%vs FY2024
Analyst consensus
RatingBuy
Target price—
2
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$1.15 · Revenue est —
View